A 58-Year-Old Man With Advanced Renal Cell Carcinoma
Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.
Case: A 58-Year-Old Man With Advanced Renal Cell Carcinoma
- August 2018: A 58-year-old man complained of fatigue and anorexia; after appropriate workup the patient was diagnosed with clear cell renal cell carcinoma
- He underwent left total nephrectomy
- March 2019: He developed metastatic disease to the lungs bilaterally (30 x 35 mm), mediastinum and soft tissue metastatic deposits
- MSKCC risk status: intermediate
- ECOG 1
- He was started on pembrolizumab 200 mg IV every 21 days + axitinib 5 mg PO q2Days
- September 2019: He developed progressive disease (45 x 50 mm); pulmonary lymph nodes increased in size and new mediastinal and hilar lymphadenopathy was noted
- He was started on lenvatinib 18 mg PO qDay + everolimus 5 mg PO qDay
- October 2019: Due to grade 1 diarrhea, reduced dose of lenvatinib to 14 mg PO qDay + everolimus 5 mg PO qDay
- December 2019: Lesions reduced to 20 x 20 mm from September 2019; achieved partial response
- January 2020: He remained on therapy with lenvatinib + everolimus
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
